Vaxcyte Quarterly Cash Flow Statement
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
71.38+6.37 (+9.79%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vaxcyte free cash flow
In the quarter ended Jun 30, 2026, Vaxcyte generated -$232.5 million of operating cash flow and spent $4.3 million on capital expenditures. That left free cash flow of -$236.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Vaxcyte cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -284.30M | -320.62M | -246.51M | -212.83M | -166.57M | -140.72M | -137.08M | -103.12M | -128.70M | -95.02M | -180.80M | -92.66M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.00M | 2.95M | 7.50M | 3.06M | 2.88M | 2.96M | 2.86M | 1.79M | 1.35M | 999.00K | 888.00K | 806.00K |
| Stock-Based Compensation | 41.24M | 37.96M | 36.00M | 35.31M | 36.93M | 30.61M | 24.37M | 21.27M | 21.56M | 17.63M | 13.35M | 13.22M |
| Change in Working Capital | -15.20M | -32.72M | 17.42M | 6.63M | 2.05M | -40.11M | 17.53M | 10.02M | -47.87M | -7.26M | 8.91M | -1.76M |
| Operating Cash Flow | -232.47M | -280.63M | -224.83M | -143.31M | -121.17M | -166.27M | -111.40M | -60.71M | -121.39M | -159.12M | -128.81M | -57.55M |
| Capital Expenditures | -4.32M | -2.11M | -2.65M | -3.82M | -1.81M | -5.42M | -4.02M | -4.95M | -7.78M | -5.68M | -5.25M | -7.34M |
| Investing Cash Flow | 147.72M | -233.41M | 115.13M | 121.17M | 77.74M | 123.32M | -557.17M | -917.02M | -80.41M | -451.07M | -13.93M | 22.28M |
| Financing Cash Flow | 5.70M | 601.58M | 2.41M | -3.67M | 2.52M | 759.00K | 4.91M | 1.52B | 110.37M | 818.20M | 2.73M | 48.55M |
| Net Change in Cash | -77.65M | 86.88M | -107.12M | -25.52M | -40.11M | -41.03M | -662.31M | 531.73M | -92.84M | 214.06M | -147.68M | 14.33M |
| Free Cash Flow | -236.79M | -282.73M | -227.49M | -147.13M | -122.98M | -171.70M | -115.42M | -65.66M | -129.18M | -164.80M | -134.06M | -64.89M |
This table shows 12 quarterly periods of Vaxcyte's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PCVX's reporting calendar. What is a cash flow statement?